Phase 2 N=5 Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
Lymphoma
Primary: Overall Response Rate After 2 Courses of Treatment
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Efficacy Study of a Cosmetic Lotion in the Treatment of Androgenetic Alopecia in Males and Females
Androgenetic Alopecia
Primary: Change of the Amount of Hair Loss in a Pull Test — 2.75 Fallen hair
Phase 3 N=33 Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
Type 2 Diabetes Mellitus · Healthy
Primary: Myocardial Glucose Uptake. — 7.46; 7.22; 0.05; 20.89 umol/min/100g
Phase 3 N=380 Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers
Aspirin-Associated Gastric Ulcers
Primary: Number of Subjects Monitored for Long-term Safety of PA32540 — 379 participants
Phase 1 N=627 Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.
Prophylaxis of A/H3N2v Influenza
Primary: Number of Subjects (3 to <9 Years of Age) Reporting Solicited Adverse Events (AEs) Following Vaccination With H3N2 Monovalent Vaccine. — 31; 36; 18; 24 Number of Subjects
N/A N=39 Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease
Lung Cancer
Primary: To Prospectively Collect Data on Chest CT Screening for Patients at Increase Lung-cancer Risk After Hodgkin's Disease. — 0 participants
N/A N=1,333 Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
Pulmonary Arterial Hypertension
Primary: Prevalence of Respiratory Tract-Related Adverse Events of Interest — 52; 51; 16; 14 percentage of participants
Phase 2 N=4 Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL
Cutaneous T-cell Lymphoma · Mycosis Fungoides · Sezary Syndrome
Primary: Number of Participants With a 50% Improvement in Baseline Skin Score — 0 participants
Phase 4 N=38 Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
Impetigo · Folliculitis · Secondarily Infected Eczema
Primary: Number of Participants Whose Wound Cultures Were Positive for MRSA and Who Were Determined to be a Clinical Success at the Follow-up Visit — 5 participants
Phase 2 N=31 PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder
Bladder, Neurogenic
Primary: Percentage of LPP Responders for Group D-Denovo and Group D-527.51 Rollover — 73.1; 35.7; 26.7; 67.9 percentage of responders
N/A N=77 Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
Shingles
Primary: Number of Participants With Innate Immunity Signatures That Correlate With the T Cell Adaptive Immunity Responses After ZOSTAVAX — 44; 33 participants
Phase 2 N=256 A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP) at Week 26 — 29.0; 30.3; 27.4; 39.1 percentage…
Phase 1 N=8 A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)
Type 2 Diabetes Mellitus
Primary: Area Under the Plasma Concentration-Time Profile From Time Zero to Time of the Last Quantifiable Concentration (AUC Last) (Dose Normalized to 1 mg) and Absolute Oral…
Phase 2 N=61 Synera Venipuncture Pain
Pain · Phlebotomy · Palliative Care
Primary: Percentage of Patients With No or Minor Pain (VAS<3) — 38.0; 21.3 percentage of participants
Phase 2 N=70 Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis
Primary: Coefficient of Fat Absorption (CFA) — 71.0; 70.9; 71.8; 75.9 percentage of fat intake